Department of Chemistry-Biology, University of Sonora, Blvd. Luis Encinas y Rosales s/n, Hermosillo, Sonora C.P. 83000, Mexico.
Departament of Physics, University of Sonora, Hermosillo, Sonora CP. 83000, Mexico.
Colloids Surf B Biointerfaces. 2022 Jul;215:112475. doi: 10.1016/j.colsurfb.2022.112475. Epub 2022 Mar 23.
Sonoran propolis (SP) exerts remarkable biological activities attributed to its polyphenolic composition, mostly described as poplar-type flavonoids. It is known that polyphenols present low bioavailability derived of their molecular weight, glycosylation level, metabolic conversion, as well as interaction with the intestinal microbiota, affording limitations for possible in vivo applications. The aim of this work was to synthesize Poly-(lactide-co-glycolide) acid (PLGA) nanoparticles for encapsulation of SP, as a matrix to increase solubility of their polyphenolic compounds and improve delivery, for the evaluation of its antiproliferative activity on cancer cells. The Sonoran propolis-loaded PLGA nanoparticles (SP-PLGA NPs) were synthesized (by nanoprecipitation), and their physicochemical parameters were determined (size, morphology, zeta potential, stability, and drug release). Additionally, the antiproliferative activity of SP-PLGA nanoparticles was evaluated in vitro against murine (M12.C3.F6) and human (HeLa) cancer cell lines, including a non-cancer human cell line (ARPE-19) as control. SP-PLGA NPs presented a mean size of 152.6 ± 7.1 nm with an average negative charge of - 21.2 ± 0.7 mV. The encapsulation yield of SP into PLGA system was approximately 68.2 ± 6.0% with an in vitro release of 45% of propolis content at 48 h. SP-PLGA NPs presented antiproliferative activity against both cancer cell lines tested, with lower IC values in M12.C3.F6 and HeLa cell lines (7.8 ± 0.4 and 3.8 ± 0.4 μg/mL, respectively) compared to SP (24.0 ± 4.3 and 7.4 ± 0.4 μg/mL, respectively). In contrast, the IC of SP-PLGA NPs and SP against ARPE-19 was higher than 50 µg/mL. Cancer cells treated with SP and SP-PLGA NPs presented morphological features characteristic of apoptosis (cellular shrinkage and membrane blebs), as well as elongated cells, effect previously reported for SP, meanwhile, no morphological changes were observed with ARPE-19 cells. The obtained delivery system demonstrates appropriate encapsulation characteristics and antiproliferative activity to be used in the field of nanomedicine, therefore SP could be potentially used in antitumoral in vivo assays upon its encapsulation into PLGA nanoparticles.
索诺拉蜂胶(SP)表现出显著的生物学活性,这归因于其多酚类成分,主要描述为杨属型类黄酮。众所周知,由于其分子量、糖基化水平、代谢转化以及与肠道微生物群的相互作用,多酚类化合物的生物利用度较低,这为可能的体内应用带来了限制。本工作的目的是合成聚(乳酸-共-乙醇酸)酸(PLGA)纳米粒子来包封 SP,作为增加其多酚类化合物溶解度并改善递送的基质,以评估其对癌细胞的抗增殖活性。索诺拉蜂胶负载的 PLGA 纳米粒子(SP-PLGA NPs)通过纳米沉淀法合成,并测定其物理化学参数(大小、形态、Zeta 电位、稳定性和药物释放)。此外,还评估了 SP-PLGA 纳米粒子在体外对鼠(M12.C3.F6)和人(HeLa)癌细胞系的抗增殖活性,包括作为对照的非癌细胞系(ARPE-19)。SP-PLGA NPs 的平均粒径为 152.6±7.1nm,平均负电荷为-21.2±0.7mV。SP 包封入 PLGA 体系的包封率约为 68.2±6.0%,48 小时内蜂胶含量的体外释放率为 45%。SP-PLGA NPs 对两种测试的癌细胞系均表现出抗增殖活性,在 M12.C3.F6 和 HeLa 细胞系中的 IC 值分别为 7.8±0.4 和 3.8±0.4μg/mL,低于 SP 的 24.0±4.3 和 7.4±0.4μg/mL。相比之下,SP-PLGA NPs 和 SP 对 ARPE-19 的 IC 值高于 50μg/mL。用 SP 和 SP-PLGA NPs 处理的癌细胞表现出细胞收缩和细胞膜泡等特征,这是细胞凋亡的特征,以及伸长的细胞,这是之前报道的 SP 的作用,同时,ARPE-19 细胞没有观察到形态变化。所得递药系统显示出适当的包封特性和抗增殖活性,可用于纳米医学领域,因此 SP 可在其封装到 PLGA 纳米粒子后潜在地用于体内抗肿瘤试验。